SouthernWorldwide.com – A new obesity treatment, retatrutide, is showing promise in helping individuals preserve muscle mass during weight loss, a critical factor often compromised by older weight-loss medications.
Neuroscientist Dr. Andrew Huberman discussed the advancements in GLP-1 (glucagon-like peptide-1) therapies, including retatrutide, on Gwyneth Paltrow’s podcast. He highlighted how previous generations of weight-loss drugs primarily focused on appetite suppression.
While effective in reducing food intake, these older medications often led to significant and rapid caloric deficits. This aggressive calorie reduction frequently resulted in a substantial loss of lean muscle mass, alongside fat.
“People would lose a ton of weight, but they would also lose muscle mass,” Huberman explained to Paltrow. This loss of muscle can have detrimental effects on metabolism and overall body composition.
Retatrutide represents a significant leap forward because it acts as a triple agonist. This means it targets three key hormonal pathways involved in regulating metabolism, blood sugar, and appetite: GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon.
By engaging these three pathways, retatrutide offers a more balanced approach to weight management. Huberman described it as a “more mild agonist of GLP-1,” which also increases glucagon and GIP activity. This multi-faceted action is believed to contribute to its effectiveness and potentially reduce side effects.
In clinical trials, retatrutide is administered as a weekly subcutaneous injection. Early findings suggest that this triple-agonist mechanism may lead to a lower side effect profile compared to previous single or dual-action drugs.
Crucially, Huberman pointed out that retatrutide appears to offer a “muscle sparing effect.” This is a significant development for individuals focused on both weight loss and maintaining a healthy body composition, particularly those engaged in fitness and longevity pursuits.
The drug has the potential to help individuals lose up to a third of their body weight over approximately a year. This gradual and potentially more sustainable weight loss, combined with muscle preservation, could offer substantial health benefits.
However, with the growing interest in these advanced weight-loss treatments, a significant “gray market” has emerged. Compounding pharmacies and online peptide suppliers are offering products that claim to be retatrutide, often before the drug has completed its official regulatory review.
Huberman issued a stern warning about sourcing these medications from unregulated channels. He explained that while these suppliers might claim high purity, the remaining percentage could contain harmful contaminants.
“One injection isn’t gonna do it, but multiple injections over time, I could see where that could become problematic,” he cautioned. Specifically, he mentioned the risk of lipopolysaccharides (LPS), a type of bacterial toxin that can cause inflammation.
Paltrow echoed these concerns, drawing a parallel to the unregulated supplement market of the 1990s. She emphasized the lack of third-party testing and the reliance on word-of-mouth for these unverified products.
Both experts strongly advised against using any products claiming to be retatrutide obtained from unverified online sources. They stressed the importance of consulting with a medical doctor.
“Multiple injections over time, I could see where that could become problematic.”
Retatrutide is currently an investigational molecule. According to the manufacturer, Lilly, it is legally available only to participants in their clinical trials. The company is actively evaluating the drug’s safety and efficacy.
Read more : SpaceX's IPO Plans Hint at Exploring the Universe's True Nature
Experts advise that the drug has not yet been reviewed or approved by any regulatory agency. Therefore, individuals should not consider taking any substance claiming to be retatrutide outside of a Lilly-sponsored clinical trial.
